<DOC>
	<DOCNO>NCT01495533</DOCNO>
	<brief_summary>The purpose study examine treatment coronary Bare Metal Stent restenosis drug coat AngioSculpt score balloon .</brief_summary>
	<brief_title>Paclitaxel-coated Uncoated AngioSculpt Scoring Balloon Catheter</brief_title>
	<detailed_description>Prospective , control , multicenter , randomize , single-blind trial . The aim examine treatment coronary Bare Metal Stent restenosis drug coat AngioSculpt score balloon . Patients randomize treatment AngioSculpt score balloon ( drug coating ) drug coat AngioSculpt score balloon ( paclitaxel 3.0 µg/mm² ) . Primary efficacy endpoint late lumen loss in-segment 6 month . Key secondary endpoint include procedural Success , MACE ( cardiac death , target vessel myocardial infarction , clinically drive target lesion revascularization 6 month ) . Individual clinical endpoint include stent thrombosis ( ARC ) , cardiac death , death , target vessel myocardial infarction , infarction , clinically drive target lesion revascularization , clinically driven target vessel revascularization , revascularization .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>&gt; 18 year age clinical evidence stable unstable angina positive functional study patient ≤ 2 primary instent restenosis ( ISR ) lesion ( ≥ 70 % diameter stenosis ) within previously place bare metal stent ( BMS ) acute myocardial infarction within past 72 hour chronic renal insufficiency serum creatinine level &gt; 2.0 mg per deciliter % know hypersensitivity contraindication aspirin , heparin , clopidogrel , ticlopidine paclitaxel , sensitivity contrast medium amenable premedication concomitant medical illness associate lifeexpectancy less two year stented segment length ≥30 mm , vessel diameter &lt; 2.5 mm , diameter stenosis &lt; 70 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>